GlobeNewswire BiotechnologyCodex · 实盘不做把握 9/10
北京时间·🕒 发布 04:01:00时区推断·⟳ 抓取 04:03:05·⚡ 决策 08-04 04:19:44 +16m39s·84.7 天前
argenx将于9月17日召开临时股东会审议两名非执行董事任命
公告仅为临时股东会通知，议题为任命Thomas M. Brakel和Khurem Farooq为非执行董事。
📄 原文GlobeNewswire Biotechnology↗ 原文
argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026
August 3, 2026 – 22:01 PM CEST Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology in…
不做 argenx（ARGX.US）
例行股东会和董事任命通知，没有可量化经营或估值催化，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-03 · 扩散 low · price-in 风险 low ↗
消息传播链
- 公司公告9月17日召开临时股东会，议程仅包括两名非执行董事任命。市场反应:ARGX.US当日收于830.27美元，下跌2.76%，但该公告本身无方向性。
关键理由
- 公告仅为临时股东会通知，议题为任命Thomas M. Brakel和Khurem Farooq为非执行董事。
- 未披露药品审批、临床数据、商业化销售、并购、融资或盈利指引变化，对公司短期收入和利润没有可量化传导。
主要风险
- 例行治理事项不构成事件交易催化。
工具调用 · 历史记录,结果未知(3 种)
- stock_quote · 结果未知
- normalize_ticker · 结果未知
- search_processed_events · 结果未知
原文全文
展开原文 · 2,238 字
August 3, 2026 – 22:01 PM CEST
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Extraordinary General Meeting of Shareholders will be held at 15:00 CEST on Thursday, September 17, 2026 at the offices of Freshfields LLP (Netherlands), Strawinskylaan 10, 1077 XZ Amsterdam, the Netherlands.
The shareholders and all other persons entitled to attend the Extraordinary General Meeting are invited to attend. The formal notice of convocation (including information on attending the meeting in person or by proxy, requirements for notification and registration for the meeting and regarding the e-voting system) is available on the argenx website www.argenx.com and on www.abnamro.com/evoting.
Agenda
The two voting items on the agenda will be the proposed appointments of Mr. Thomas M. Brakel and Mr. Khurem Farooq as non- executive directors of the Company’s Board of Directors.
The agenda for the meeting as well as all ancillary documents relevant for the meeting are available via the argenx website and are also available for inspection at the argenx offices. A free copy thereof may also be obtained by e-mailing legal@argenx.com. argenx would like to encourage shareholders to use the voting by (electronic) proxy option as referred to in the convocation.
About argenx
argenx is a global immunology innovation company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.
Contacts
Media:
Ben Petok
Bpetok@argenx.com
Investors:
Alexandra Roy
aroy@argenx.com
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Extraordinary General Meeting of Shareholders will be held at 15:00 CEST on Thursday, September 17, 2026 at the offices of Freshfields LLP (Netherlands), Strawinskylaan 10, 1077 XZ Amsterdam, the Netherlands.
The shareholders and all other persons entitled to attend the Extraordinary General Meeting are invited to attend. The formal notice of convocation (including information on attending the meeting in person or by proxy, requirements for notification and registration for the meeting and regarding the e-voting system) is available on the argenx website www.argenx.com and on www.abnamro.com/evoting.
Agenda
The two voting items on the agenda will be the proposed appointments of Mr. Thomas M. Brakel and Mr. Khurem Farooq as non- executive directors of the Company’s Board of Directors.
The agenda for the meeting as well as all ancillary documents relevant for the meeting are available via the argenx website and are also available for inspection at the argenx offices. A free copy thereof may also be obtained by e-mailing legal@argenx.com. argenx would like to encourage shareholders to use the voting by (electronic) proxy option as referred to in the convocation.
About argenx
argenx is a global immunology innovation company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.
Contacts
Media:
Ben Petok
Bpetok@argenx.com
Investors:
Alexandra Roy
aroy@argenx.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。